CHEYENNE, Wyo., April 09, 2018 -- MedX Holdings, Inc. (OTC Pink:MEDH) through unanimous vote from a Special Board of Directors meeting has Cancelled and Retired 150 Million Common shares from the Authorized Share count effective immediately. Please visit http://soswy.state.wy.us/ for further information.
Additionally, 98,117,200 Restricted Shares were surrendered by Kathleen Roberton to Mark Miller per the Management Agreement that was executed in December of 2017. Those shares were transferred into the New CEO Mark Miller’s name and remain restricted.
Mr. Miller stated, “This share reduction helps put to rest some legacy issues from previous management that reaffirms our commitment to build investor and shareholder value. Any assets leased or owned by the past owners has nothing to do with the current state of events or assets held by MedX Holdings presently. At this point, in weighing our options, we are discussing with our accountant and attorney what our capacity will be to cancel and retire shares from the OS by 30 to 50 Million. This may require the issuance of an E Class Share to secure sole voting rights, but we have not yet crossed that bridge.”
Follow us on Twitter @MedX_Holdings
ABOUT: MedX Holdings
MedX Holdings is a Holding Company that Acquires "Real" Businesses throughout the United States that have operational track records; including the expansion of its current operations in Residential/ Commercial Construction and Real Estate.
Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the company's Forms 10-K and 10-Q filed with the SEC.
For further information contact:
Mark Miller
(612) 615-9334
[email protected]


Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 



